Last reviewed · How we verify
PP6M injection Dose 1
PP6M is a long-acting injectable contraceptive that prevents pregnancy through hormonal suppression of ovulation.
PP6M is a long-acting injectable contraceptive that prevents pregnancy through hormonal suppression of ovulation. Used for Contraception in women of reproductive age.
At a glance
| Generic name | PP6M injection Dose 1 |
|---|---|
| Also known as | R092670 |
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Progestin-only injectable contraceptive |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Women's Health |
| Phase | Phase 3 |
Mechanism of action
PP6M (progestin-only injection) is a hormonal contraceptive administered as an intramuscular injection designed to provide extended contraceptive coverage. It works by releasing a synthetic progestin that suppresses the luteinizing hormone surge necessary for ovulation, thickens cervical mucus to impede sperm transport, and alters the endometrium to prevent implantation. The formulation is engineered for prolonged drug release, providing contraceptive efficacy over an extended dosing interval.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Menstrual irregularities (amenorrhea, spotting, breakthrough bleeding)
- Headache
- Injection site reactions
- Weight changes
- Mood changes
Key clinical trials
- A Study of Paliperidone Palmitate 6-Month Formulation (PHASE3)
- A Study of Paliperidone Palmitate 6-Month Formulation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |